If you've been wondering whether you qualify for Ozempic, here's the short version before anything else: most eligibility comes down to two numbers and a short list of health conditions. A licensed provider generally considers you a candidate for semaglutide-class weight management if your BMI is 30 or higher, or if your BMI is 27 or higher and you have at least one weight-related health condition. That single rule decides eligibility for the large majority of people who ask the question.

Want your own number first? Our free 30-second eligibility check calculates your BMI and walks you through the same health questions a provider would ask — no signup, no card. Then come back here to understand what your result actually means.

This guide explains where those thresholds come from, which conditions count, how telehealth providers actually evaluate you, and what to do if you're sitting right on the borderline.

The Quick Answer

A useful way to think about eligibility is two tiers, which mirror how the medications were studied and labeled:

Tier 1 — BMI 30 or higher. If your BMI is 30 or above (the clinical threshold for obesity), you generally qualify on BMI alone. No additional condition required.

Tier 2 — BMI 27 to 29.9 with a comorbidity. If your BMI falls in the "overweight" range of 27 to 29.9, you typically qualify if you also have at least one weight-related health condition — things like type 2 diabetes, high blood pressure, high cholesterol, or obstructive sleep apnea.

One important clarification that trips many people up: Ozempic itself is FDA-approved to treat type 2 diabetes, not for weight loss. When people say "qualify for Ozempic" they usually mean "qualify for semaglutide-based weight management," and for that specific purpose the closely related drug Wegovy (also semaglutide, made by the same manufacturer) carries the weight-management approval. We'll untangle that distinction below, because it changes which medication a provider is likely to discuss with you.

Where the BMI Threshold Comes From

The 30-and-27 thresholds aren't arbitrary. They trace directly back to the clinical trials that won these drugs their approvals. The pivotal semaglutide weight-management studies enrolled adults with obesity (BMI ≥30) or adults who were overweight (BMI 27–29.9) with at least one weight-related condition such as high blood pressure or elevated cholesterol. Because that's who the drug was tested on, that's the population the label and most prescribers stay within. Prescribing meaningfully below those thresholds would be considered off-label and isn't supported by the trial evidence.

This is why your BMI is the first gate in any eligibility conversation — and why a tool that calculates it accurately, then asks the right follow-up questions, can tell you in under a minute whether a provider visit is even worth your time.

Qualifying Health Conditions (The Full List)

If your BMI is in the 27–29.9 range, the deciding factor is whether you have a qualifying weight-related condition. The ones most consistently accepted include:

  • Type 2 diabetes — often the most straightforward path, and the one indication Ozempic is directly approved for
  • Prediabetes or insulin resistance — accepted by many providers with supporting lab work
  • High blood pressure (hypertension)
  • High cholesterol or dyslipidemia
  • Obstructive sleep apnea — notably, the tirzepatide drug Zepbound now carries a specific FDA approval for this
  • Cardiovascular disease or a history of heart attack or stroke
  • Polycystic ovary syndrome (PCOS) — frequently relevant, and a reason many women qualify without realizing it

A useful real-world data point: a widely reported 2024 analysis estimated that well over 100 million U.S. adults meet the weight-management eligibility criteria for semaglutide — the vast majority through the BMI-and-comorbidity pathway rather than diabetes alone. In other words, far more people qualify than assume they do, often because a condition like sleep apnea or PCOS quietly pushes them over the line.

If you're not sure whether your conditions count, the eligibility check screens for each of these and tells you how they affect your result.

Ozempic vs. Wegovy: Different Rules for Different Goals

This is the single most common source of confusion, so it's worth being precise:

  • Ozempic (semaglutide) is FDA-approved for type 2 diabetes. Doses are 0.5 mg, 1.0 mg, and 2.0 mg. It's frequently prescribed off-label for weight loss, but that's a clinical decision between you and your provider.
  • Wegovy (also semaglutide, same manufacturer) is FDA-approved specifically for chronic weight management, dosed at 2.4 mg. This is the product whose label carries the BMI ≥30 / ≥27-with-comorbidity criteria for weight loss.

So if your goal is weight management and you don't have diabetes, the medication a provider is most likely to discuss is Wegovy (or a tirzepatide option like Zepbound), even if "Ozempic" is the word you searched. The eligibility criteria are essentially the same; the approved-on-label product differs.

One genuinely new development worth knowing: in December 2025 the FDA approved an oral semaglutide tablet for weight management, adding a non-injectable option to the mix. If needles have been your hesitation, that's worth raising with a provider.

For a deeper comparison, see our guide to Wegovy BMI requirements.

How Telehealth Providers Actually Evaluate You

Whether you see your own doctor or use a telehealth service, the evaluation follows a similar path:

  1. Measurements and BMI. Height and weight establish your BMI — the first gate.
  2. Health history. Your conditions, current medications, and family history determine whether the comorbidity pathway applies and screen for anything that would make the medication unsafe for you.
  3. Contraindication screening. Certain histories — including a personal or family history of medullary thyroid cancer or MEN 2 syndrome — are absolute reasons not to prescribe. The semaglutide label carries a boxed warning related to thyroid C-cell tumors observed in rodent studies, which is why this screening matters.
  4. The clinical decision. A licensed provider — not a calculator, and not this website — makes the actual prescribing decision based on the full picture.

A screening tool like ours can tell you whether you're likely to clear the first gates. It cannot and does not prescribe. That final judgment always belongs to a licensed clinician.

What If I'm Borderline?

Plenty of people land just under the line — a BMI of 26.4, or 28 with no diagnosed condition. A few honest things to know:

  • Undiagnosed conditions are common. Obstructive sleep apnea and PCOS in particular often go undiagnosed for years. If you have symptoms (loud snoring and daytime fatigue, or irregular cycles and other PCOS signs), getting properly evaluated may reveal a condition that changes your eligibility — and is worth addressing for its own sake, separate from any medication.
  • BMI is a blunt instrument. It doesn't distinguish muscle from fat. If you're very muscular, your BMI may overstate your body fat; if you carry low muscle mass, it may understate it. Our body fat estimate can add useful context, though providers still use BMI as the formal threshold.
  • Borderline isn't a verdict. Weight, and the conditions that come with it, change over time. A "not yet" today isn't a "never."

If your check comes back borderline, the most useful next step is usually a conversation with a provider about evaluation for the conditions above — not a workaround to game a number.

A Note on Cost and Access in 2026

Eligibility and affordability are two different questions. A few current realities worth setting expectations around:

  • Insurance coverage for weight loss is inconsistent. Many plans cover semaglutide for diabetes far more readily than for weight management. Coverage for weight loss alone varies widely by plan and by state.
  • Brand-name cash prices are high but moving. Medicare selected semaglutide products in its drug price negotiations, with negotiated pricing scheduled to take effect in 2027 — a sign of broader pricing pressure ahead.
  • The compounded-medication landscape changed sharply. During the 2022–2024 shortages, compounded semaglutide and tirzepatide were widely available at lower prices. Both shortages have since been declared resolved (tirzepatide in late 2024, semaglutide in early 2025), and in April 2026 the FDA proposed further restricting large-scale compounding. The practical takeaway: the cheap-compounded era is narrowing, and anyone considering that route should understand that compounded preparations are not themselves FDA-approved products and the regulatory picture is actively shifting.

We cover the full cost breakdown in our Ozempic cost guide. The key point for this article: clearing the eligibility bar doesn't automatically mean affordable access, so it's worth understanding both.

How to Get Started

If you've read this far, the most efficient next step is to get your actual numbers and a clear read on which tier you fall into:

  1. Take the free 30-second eligibility check. Enter your height, weight, and health information. You'll get an instant BMI and a clear eligibility read — qualified, borderline, or not currently eligible — with no signup required.
  2. Review your result. If you qualify or you're close, the tool explains what that means and what your options are.
  3. Talk to a licensed provider. Only a clinician can prescribe. If you'd like to explore treatment, we can show you licensed telehealth providers — but the decision is always yours and theirs, not ours.

Frequently Asked Questions

What BMI do I need to qualify for Ozempic or Wegovy? Generally a BMI of 30 or higher qualifies on its own. A BMI of 27 to 29.9 typically qualifies if you also have at least one weight-related condition such as type 2 diabetes, high blood pressure, high cholesterol, or sleep apnea. A licensed provider confirms eligibility.

Is Ozempic the same as Wegovy? Both contain semaglutide and are made by the same manufacturer, but they're approved for different purposes. Ozempic is approved for type 2 diabetes; Wegovy is approved for chronic weight management. For weight loss specifically, Wegovy is the on-label product, though Ozempic is sometimes prescribed off-label.

Can I qualify with a BMI under 27? Below a BMI of 27, semaglutide-based weight management generally isn't supported by the clinical evidence or the drug labeling, so most providers won't prescribe it for weight loss in that range. There are exceptions for certain medical situations, but those are decisions for a clinician.

Does PCOS help me qualify? PCOS is a weight-related condition that many providers count toward the comorbidity pathway, meaning some women with a BMI of 27 to 29.9 qualify because of it. Many people don't realize PCOS may make them eligible.

Does this website prescribe medication? No. mybmi.ai is an educational screening tool. Only a licensed healthcare provider can prescribe. We can connect you with licensed telehealth options if you choose to explore treatment.

Is there a pill version now? Yes — the FDA approved an oral semaglutide tablet for weight management in December 2025, adding a non-injectable option. Whether it's right for you is a question for your provider.

Will my insurance cover it? It depends heavily on your plan and whether the prescription is for diabetes or weight loss. Coverage for weight loss alone is far less consistent than coverage for diabetes. Check with your insurer and provider.

How accurate is a BMI-based eligibility check? BMI is the standard first gate providers use, but it doesn't distinguish muscle from fat and isn't the whole picture. A screening tool can tell you whether you likely clear the thresholds; a provider makes the actual clinical determination.

Medical Disclaimer

mybmi.ai provides general health and wellness information for educational purposes only. This article and our eligibility check are not medical advice, diagnosis, or treatment. Body Mass Index is a screening tool with known limitations and should not be the sole factor in any medical decision. Always consult a licensed healthcare provider before starting, stopping, or changing any medication, including GLP-1 receptor agonists.

Affiliate Disclosure

mybmi.ai may receive compensation from telehealth providers when users sign up through links on this site. This does not affect what you pay or which providers we display. See our full Affiliate Disclosure.

Trademark Notice

Ozempic® and Wegovy® are registered trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. mybmi.ai is not affiliated with, endorsed by, or sponsored by any pharmaceutical manufacturer.